Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Headlands Research

Neither a doctor nor a teaching hospital

Research payments

$1,038,552

54 payments

Through program year 2025, Headlands Research is reported as receiving $1,038,552 in research payments, across 54 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $163,694 32
2024 Research $420,856 19
2023 Research $398,214 2
2022 Research $55,789 1

Breakdown

Who paid Research payments · program years 2022–2025
  1. Biogen, Inc. $695,688 8 payments
  2. Eisai Inc. $180,185 10 payments
  3. Alnylam Pharmaceuticals Inc. $99,630 16 payments
  4. Roche Molecular Systems, Inc. $48,260 13 payments
  5. Pfizer Inc. $14,457 5 payments
  6. Moderna TX, Inc. $333 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $648,566 5 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $180,185 10 payments
  3. A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) $99,630 16 payments
  4. Rd006866 $48,260 13 payments
  5. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $35,862 2 payments
  6. A Phase 2, randomized, multicenter, two-arm, open-label study to compare the pharmacodynamics, safety, and tolerability of subcutaneous versus intravenous administration of Aducanumab (BIIB037) in participants with Alzheimer's disease $11,260 1 payment
  7. A Phase 3 Randomized Openlabel Trial to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine Formulated in Multidose Vials in Healthy Female Adults $9,385 1 payment
  8. A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $2,133 1 payment
  9. A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $1,659 2 payments
  10. A Phase 3 Protocol to Investigate the Safety Tolerability and Immunogenicity of A Bnt162b2 Lp81adapted Vaccine in Children 5 Through 11 Years of Age Considered at High Risk for Severe Covid19 $1,280 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record